REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH) today announced the closing of its initial public offering of 14,375,000 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,875,000 additional shares of common stock, at a public offering price of $19.00 per share. The gross proceeds from the offering were approximately $273.1 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock were offered by Guardant Health. The shares commenced trading on The Nasdaq Global Select Market on October 4, 2018, under the ticker symbol “GH”.
J.P. Morgan Securities LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. Cowen and Company, LLC, Leerink Partners LLC and William Blair & Company, L.L.C. acted as co-managers for the offering.
A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on October 3, 2018. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: (866) 803-9204, or by email: prospectus-eq_fi@jpmchase.com; or BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email: dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Contacts
Investors:
Lynn Lewis or Carrie Mendivil
investors@guardanthealth.com
Media:
Josh Wein or Ian Stone
press@guardanthealth.com